Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study

R. Bissonnette*, T. Luger, D. Thaçi, D. Toth, I. Messina, R. You, A. Guana, T. Fox, C. Papavassilis, I. Gilloteau, U. Mrowietz

*Korrespondierende/r Autor/-in für diese Arbeit
30 Zitate (Scopus)

Fingerprint

Untersuchen Sie die Forschungsthemen von „Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study“. Zusammen bilden sie einen einzigartigen Fingerprint.

Medizin & Biologie